HIPRA Biotech Services is a CDMO supporting pharmaceutical and biotech companies across the full early clinical to commercial lifecycle of biologic and vaccine products. Backed by over 50 years of scientific and technical excellence including our internally commercialized and marketed COVID vaccine, we offer end-to-end development and GMP manufacturing solutions across a wide range of expression platforms, from viral to mammalian to microbial platforms, to make clinical and commercial drug substance and drug product for our clients. With a team of 450+ R&D scientists and over 1,000+ professionals in Manufacturing, QA and QC, state-of-the-art facilities, and a strong regulatory track record, we deliver both clinical and commercial programs with speed, quality, and flexibility. We continuously invest in innovation and capacity expansion, making us a trusted partner that will grow with our clients for their long-term success. https://www.hipra.com/en/cdmo-services
Groupe PARIMA
Groupe PARIMA is a Contract Development and Manufacturing Organization (CDMO), established in 1994. Over the years, we have developed an expertise in the development and manufacturing of non-sterile liquids, suspensions, and semi-solid drug products. This strategic focus has allowed us to establish a unique expertise to support your product development and manufacturing needs, which, combined to our operational flexibility and commitment to delivering on time, enables us to operate as an extension of your team. Our business is 100% fee-for-service and exclusively focused on contract services. We are here to help you meet your company objectives, not to compete with you. | Groupe PARIMA is a leading Contract Development & Manufacturing Organization (CDMO) that excels in the development and manufacturing of non-sterile pharmaceutical products. Specializing in liquids, semi-solids, and suspensions, we offer an extensive range of services focused on product development, commercial manufacturing, packaging and laboratory testing. Our modern facility is equipped to handle complex pharmaceutical formulations and packaging requirements. At the core of our operation is a deep commitment to research and development. Our expert team collaborates closely with clients to design and optimize formulations that meet specific patient needs, ensuring each product achieves optimal effectiveness and regulatory approval. This focus on development is complemented by our flexibility to scale processes seamlessly from pilot batches to clinical supply and eventually large-scale commercial production. Our team of skilled professionals bring a wealth of industry knowledge and technical expertise, making us a preferred partner for both emerging biotechs and established pharmaceutical companies across 28 countries. Groupe PARIMA’s ability to adapt swiftly to changing market conditions and client requirements sets us apart in the dynamic pharmaceutical landscape. With ample manufacturing capacity and comprehensive on-site services including laboratory testing and regulatory compliance activities, we are equipped to handle diverse project demands with precision. Whether advancing a novel treatment or expanding production capabilities, Groupe PARIMA provides the expertise and infrastructure necessary to bring your pharmaceutical products to global markets. Explore the possibilities with Groupe PARIMA as your dedicated CDMO partner. Discover our full range of development capabilities and services at www.groupeparima.com. | Groupe PARIMA, a CDMO since 1994, specializes in the development and manufacturing of non-sterile liquids, suspensions, and semi-solids. With deep expertise in complex formulations, scale-up, and regulatory compliance, we provide end-to-end support from development to commercial production. Our flexible approach, technical proficiency, and commitment to on-time delivery make us a trusted partner for pharmaceutical companies worldwide. As a dedicated contract service provider, we focus entirely on supporting our clients’ success with tailored solutions and operational agility.
GCCL
Accelerate your global trials with GCCL – All-in-One Clinical Lab Solution (Central Lab + BA Lab + R&D) GCCL, a Lab CRO based in South Korea, specializing in clinical sample analysis services for all phases of trials. With an exclusive lab service available for clinical trials and a logistics system that meets global quality standards, GCCL is building trust with over 200 partners globally by providing a sample analysis and bioanalytical service spanning the entire cycle of clinical trials to meet customer demands. Based in Korea as a strategic hub for the Asia-Pacific region, GCCL is South Korea’s only provider of a fully integrated “all-in-one lab solution,” combining a Central Lab, Bioanalytical Lab, and Biosafety Level 3/2 (BL3) facilities. This unified approach delivers consistent analytical quality, reliable data, and reduced time and costs by minimizing sample handling. Leveraging its proprietary G-HUB IT platform, cutting-edge analytical technologies, and global LIMS, GCCL provides end-to-end, high-quality clinical sample analysis services—from collection to storage—positioning itself as a trusted partner in drug development. Its dedicated R&D lab drives method development, biomarker discovery, and the evaluation of innovative analytical technologies, continuously enhancing capabilities to meet evolving clinical trial needs. -Supporting clinical trials with comprehensive laboratory services across all therapeutic areas and pipelines (from sample collection and kit production to analysis and storage) -Collaborating on R&D for pipelines, including biosimilars, bioanalysis, assays, and more -Offering clinical trial consulting, including study design and regulatory/approval support
Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable, end-to-end manufacturing services. Offerings include process and analytical development, plasmid DNA manufacturing, viral vector manufacturing, final fill, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com. | Forge Biologics, a member of Ajinomoto Biopharma Services, is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company, enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and regulatory consulting support to help accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit www.forgebiologics.com. | Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a gene therapy contract development and manufacturing organization (CDMO) enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 20,000L of bioreactor capacity. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases. To learn more, visit www.forgebiologics.com | Forge Biologics, a member of Ajinomoto Bio-Pharma Services, is a gene therapy contract development and manufacturing organization (CDMO) enabling access to life-changing gene therapies by bringing them from concept to reality. Forge’s 200,000 square foot facility, the Hearth, is headquartered in Columbus, Ohio, and houses 20 custom-designed cGMP suites with 20,000L of bioreactor capacity. Forge’s end-to-end, scalable plasmid and AAV manufacturing services include research-grade manufacturing, process and analytical development, cGMP manufacturing, fill and finish, and integrated regulatory support to help accelerate the timelines of transformative medicines for patients with genetic diseases.
FAREVA
Farera as a CDMO is providing a large service offer as sterile injectable and high potent, biological drug, conventionnal product, medial devices, foods supllements and probiotics as well as Drug substance manufacturing of recombinant protein, Andibody Dug Conjugason (ADC) with the associated Fill& Finish | FAREVA is a leading global pharmaceutical CDMO with industry leading capabilities in the development and manufacturing of a large range of Drug Products and Active Pharmaceutical Ingredients (APIs). FAREVA employs 13,000 people distributed in 41 production sites located in 13 countries in EMEA and the Americas. 16 of the FAREVA sites are dedicated to pharmaceutical activities. FAREVA’s API division has operations in 3 European sites located in France and Germany. | Fareva is a leading global pharmaceutical CDMO with a network of 16 manufacturing sites and 3 development sites throughout EMEA and the Americans. We offer comprehensive drug product and API services, including formulation development, clinical manufacturing, scale-up, and commercial manufacturing of small and large molecules. Our capabilities cover a wide range of dosage forms, such as OTC products, oral solid doses, non-sterile liquids and solids, ophthalmics, as well as sterile fill/finish and lyophilized presentations. In addition, our facilities have extensive expertise in secondary packaging, enabling us to serve as a fully integrated partner for our clients’ end-to-end pharmaceutical needs.
Experic
Experic is a contract development and manufacturing organization (CDMO) and clinical trial supply services company dedicated to revolutionizing pharmaceutical development, manufacturing, and clinical trial supply. Established in 2018, Experic offers a comprehensive suite of services, including process development, analytical and formulation development, clinical and commercial manufacturing, and clinical packaging and logistics. Specializing in challenging powders and inhalation products, our expertise encompasses tablets, pellets, capsules, and low-dose dry powder inhalation therapies. Operating from our state-of-the-art, Class A cGMP facility in Cranbury, New Jersey, we manage the global delivery of high-quality products, even for expedited projects. Our team of industry leaders brings decades of experience in pharmaceutical product development and clinical trial supplies, ensuring strategic vision and execution for every project. At Experic, we are committed to delivering innovative, client-focused services that accelerate the development and commercialization of life-changing therapies. Our flexible, customer-oriented approach addresses the growing needs of the biopharmaceutical industry, making us a trusted partner in bringing innovative products to market.
eXmoor Pharma
eXmoor is a full service Cell & Gene Therapy CDMO with a difference. We are backed by 20 years CMC consultancy experience, supporting over 150 organisations to accelerate novel therapies from discovery to patients. We provide expert solutions at all stages of the development journey from early process development and scale-up through to GMP manufacture, fill and finish and QP release. We are open, transparent and will work with you at every step to de-risk and streamline your project and maximise the chances of product success. | eXmoor Pharma is a full-service Cell & Gene Therapy CDMO with a difference. Backed by over 20 years of consultancy experience, we’ve helped more than 170 organisations accelerate therapies from discovery to delivery. We deliver more than manufacturing. Our integrated consultancy and technical development services span the full journey from early-phase strategy to GMP manufacturing and commercialisation. Our in-house experts work as an extension of your team, helping you plan, scale, and deliver therapies that are clinically and commercially viable. We bring deep domain knowledge across process development, analytical science, facility design, GMP production, and regulatory strategy. With a purpose-built facility and a commitment to full IP freedom, we give innovators the space and flexibility to focus on what matters most: getting life-changing treatments to patients faster.
EuBiologics
EuBiologics is listed biopharmaceutical company located in Korea, developing human vaccines against infectious disease using two proprietary technologies, EcML (Monophosphoryl Lipid A, TLR4 agonist) and recombinant CRM197 (Carrier protein). We have currently 7 vaccines in the pipeline. TCV (Typhoid Conjugate Vaccine, NDA), PCV (Pneumococcal Conjugate Vaccine, Ph I completed), MCV (Meningococcal Conjugate Vaccine, Ph I completed), HZV (Herpes Zoster Virus, Non-Clinical), RSV (Respiratory Syncytial Virus, Non-clinical), OCV (Oral Cholera Vaccine, commercialized) and EuCorVac-19 (COVID-19, Ph III). OCV have been supplied to UNICEF/PAHO and several more countries since 2016 after WHO-PQ and captured more than 90% of the public cholera vaccine market. EuBiologics can also offer advanced cGMP-level facilities providing fully integrated CRMO services for mammalian cell and microbial derived biopharmaceutical, from cell line development to large-scale commercial GMP production. EuBiologics is especially specialized in a variety of protein-based therapeutics and vaccines as we have had plenty of experience working with many innovative biotech in getting the right therapeutics. We possess extensive working knowledge of developing and manufacturing different types of vaccine. | EuBiologics is a publicly traded biopharmaceutical company specializing in human vaccines targeting infectious diseases. We leverage our proprietary adjuvant (TLR4 agonist, E. coli-derived) and recombinant carrier protein (CRM197), both of which have global IP protections, to develop novel vaccines. | x
EMD Serono
EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany, in the US and Canada, is a science-led organization dedicated to making a meaningful difference in the lives of people affected by cancer. Our oncology research aims to leverage our synergistic portfolio to tackle challenging tumor types, as we work to illuminate a path to scientific breakthroughs to transform patient outcomes. Learn more at www.emdseronooncology.com | We are the healthcare business in the U.S.A. & Canada for Merck KGaA, Darmstadt, Germany, a vibrant science and technology company. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are curious minds dedicated to human progress. | In Healthcare, we are at the forefront of developing pioneering therapies – boldly aiming to meaningfully change the lives of patients, their families, and their caregivers. We are unlocking leaps in highly specialized fields with significant unmet medical needs. We leverage internal discoveries and external partnerships to serve patients who need it most across all continents. As one company, science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are sparking discovery, elevating humanity. | We are the healthcare business in the U.S.A. & Canada for Merck KGaA, Darmstadt, Germany, a vibrant science and technology company. EMD Serono Aspires to create, improve and prolong lives — As One for Patients. Science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. The passion of our curious minds makes a positive difference to millions of people’s lives every day. In Healthcare, we discover unique ways to treat the most challenging diseases, such as multiple sclerosis and cancer. Our Life Science experts empower scientists by developing tools and solutions that help deliver breakthroughs more quickly. And in Electronics, we develop science that sits inside technologies and changes the way we access, store, process, and display information. Everything we do is fueled by a belief in science and technology as a force for good. A belief that has driven our work since 1668 and will continue to inspire us to find more joyful and sustainable ways to live. We are curious minds dedicated to human progress.